2009 Agenda

This is the Agenda for the European Life Science CEO Forum – to view the Biotech in Europe Investor Forum Agenda click here

Agenda
Tuesday 3 February 2009
08.00
Registration
09.00
Welcome by Host Sponsor
Yvonne Gunsch-Wegmann, Vice President, Head of Issuer & Investor Relations, SIX Swiss Exchange
09.10
Panel Discussion: M&A
Chair: Ms. Stephanie Léouzon, Managing Director Healthcare, Credit Suisse
Panellists:

Vincent Mutel, CEO, Addex Pharmaceuticals Ltd
Dr Karl Nägler, Principal, Atlas Venture
Laurent Feniou, Director, Rothschild
09.50
Panel Discussion: Investor Perspective
Chair: Dr Genghis Lloyd-Harris, Partner, Abingworth Management Ltd
Panellists: Jesper Zeuthen, Managing Director, BankInvest Biomedical Venture
Roel Bulthuis, Senior Director, Head of Merck Serono Ventures, Merck Serono International
Dr Ulrik Spork, Senior Partner, Novo Ventures
Antoine Papiernik, Managing Partner, Sofinnova Partners
10.30
Coffee Break
Company Presentations: Public & Private Companies
Room 1   Room 2
10.50
Biotie Therapies Corp.   Wilex AG
11.05
Addex Pharmaceutical Ltd.   MolMed S.p.a
11.20
VIVUS, Inc.   Reneuron Group Plc
11.35
LifeCycle Pharma A/S   AVIR Green Hills Biotechnology
11.50
BioXell   Agendia
12.05
Archimedes Pharma   immatics biotechnologies GmbH
12.20
Clinuvel   United Technologies UT AG
12.35
    United Technologies UT AG
13.00
Lunch
14.00
Company Presentations: Private Companies
Room 1   Room 2
14.00
Lectus Therpauetics   FCMB Aps
14.15
Cellerix   Pronota nv
14.30
tecData   DBV Technologies
14.45
ESBATech AG   Fibrex Medical Inc.
15.00
Nitec Pharma   SpinX Technology
15.15
Lumavita AG   Scil Technology
15.30
ImVision GmbH   Xceleron
15.45
Axial Biotech, Inc.   Provecs
16.00
Syntaxin Ltd   Selvita Sp. Z.o.o
16.15
Axentis Pharma   Altacor Pharma
16.30
Coffee Break
16.45-17.45
Midsized Pharma Discussion Panel
Chair: Dimitri Dimitriou, Chief Executive Officer, DyoDelta Biosciences
Panellists: Massimo Radaelli, President & CEO, Dompé International SA
Dr Xavier Pagès, Director, International Affairs, Business Development & Licensing, Esteve
Dr Fintan Walton, CEO, PharmaVentures Ltd
Dr Paolo Bessieres, CEO, PharmaWave Ltd
Rudy Tubbeh, Managing Director, Sager Pharma Kft.
17.45-19.45
Networking Reception
 

 
Agenda
Wednesday 4 February 2009
08.00
Registration
09.00
Partnering Trends Panel
Chair: Dimitri Dimitriou, Chief Executive Officer, DyoDelta Biosciences
Panellists: Lubor Gaal, Executive Director, Head of Europe, Strategic Transactions Group, Bristol-Myers Squibb
Dr Margaret Beer, Senior Director and Head, Licensing and External Research, Europe, Merck & Co
François Conquet, Director Early Stage Licensing, Merck Serono International SA
Markus Ewert, Global Head, Search & Evaluation, Novartis Pharma AG
Alex Chanas, Senior Director, Worldwide Licensing and Business Development, Pfizer Inc.
10.05
Panel Discussion: Survival Strategies: Opportunities & threats in current market
Chair: Karl Keegan, Managing Director, Life Sciences Analyst, Canaccord Adams
Panellists: Geoffroy de Ribains, Analyst, Edmond de Rothschild Investment Partners
Michèle Ollier, Principal, Index Ventures
Anthony Hartley, Executive Director, Morgan Stanley | Investment Banking Division
Yvonne Gunsch-Wegmann, Vice President, Head of Issuer & Investor Relations, SIX Swiss Exchange
Karen Wagner, PhD, Venture Partner, Ysios Capital Partners SGECR SA
10.55
Coffee Break
11.15
Pharma Partnering Presentations
11.15
Nigel Sheail, Vice President, Global Head Licensing, Pharma Partnering, Roche Pharmaceuticals
11.30
Markus Ewert, Global Head, Search & Evaluation, Novartis Pharma AG
11.45
Dr Margaret Beer, Senior Director and Head, Licensing and External Research, Europe, Merck & Co
12.00
François Conquet, Director Early Stage Licensing, Merck Serono International SA
12.15
Lubor Gaal, Executive Director, Head of Europe, Strategic Transactions Group, Bristol-Myers Squibb
12.30
Networking Lunch
14.00
1-2-1 Meetings
17.00
Close of Conference

 

Back to top